Viracta Therapeutics, Inc.
VIRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VIRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2024.
Tracking 1 pipeline candidate · 1 clinical trial for Viracta Therapeutics, Inc..
Run Viracta Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Viracta Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
8.9 months
OCF -$7M · Net income -$11M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Viracta Therapeutics, Inc.'s lead drug candidate?
Viracta Therapeutics, Inc.'s most advanced tracked candidate is nana-val (Phase 1) for EBV-positive recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and other EBV+ solid tumors.
Who is the CEO of Viracta Therapeutics, Inc.?
California Table is the chief executive officer of Viracta Therapeutics, Inc. (VIRX).
What therapeutic areas does Viracta Therapeutics, Inc. focus on?
Viracta Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.